Porcine Vaccine Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2022-2027
Porcine Vaccine Market Overview
Porcine Vaccine Market size is estimated to reach $2.12 billion by 2027, growing at a CAGR of 7.1% during the forecast period 2022-2027. Porcine Vaccines indicate clinical as well as an administrative medication that improves swine health by safeguarding them from an assortment of bacteria, viruses and additional pathogens. Porcine vaccine may involve porcine gelatine which is utilized in vaccines as a stabilizer to guarantee that the vaccine stays safe and effective at the time of storage. Vaccine makers usually test an extensive series of stabilizers and select one that is stable, has good quality and is accessible in adequate volume. Improvac is an immunological medication utilized in male pigs to decrease ‘boar taint’ in the meat acquired from them subsequent to slaughter. Boar taint is the offensive smell or taste which may be existing in pork or pork products from non-castrated mature male pigs. Suvaxyn PRRS MLV is a veterinary vaccine utilized to safeguard pigs against porcine respiratory and reproductive syndrome (PRRS). Circovac is a vaccine utilized to safeguard pigs against porcine circovirus type 2 (PCV2). Immunization with a recombinant fusion of porcine reproductive and respiratory syndrome virus modified GP5 and ferritin draws out improved safeguarding immunity in pigs. Toxoid vaccines utilize toxoids (as antigens) to encourage an immune response in safeguarding against diseases brought about by toxins secreted by particular bacteria. A conjugate vaccine is a kind of subunit vaccine which integrates a weak antigen with a powerful antigen as a carrier so that the immune system has a more powerful response to the weak antigen.
The burgeoning R&D activities by key players for the discovery of new porcine vaccine to treat ailments and the heightening product approvals are set to drive the Porcine Vaccine Market. The increasing predominance of ailments amidst animals owing to viruses and bacteria and the emerging awareness amidst a big block of the population in terms of vaccinating the animals like pigs to safeguard them with vaccines like Suvaxyn and Circovac are set to propel the growth of the Porcine Vaccine Industry during the forecast period 2022-2027. This represents the Porcine Vaccine Industry Outlook.
Porcine Vaccine Market Report Coverage
The “Porcine Vaccine Market Report - Forecast (2022-2027)” by Industry ARC, covers an in-depth analysis of the following segments in the Porcine Vaccine Market.
Porcine Vaccine Market: Market Share (%) By Region, 2021
For More Details On this report - Request For Sample
The Porcine Vaccine Market based on target disease can be further segmented into Diarrhoea, Swine Influenza, Arthritis, Bordetella Rhinitis, Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Associated Disease (PCVAD) and Others. The Porcine Circovirus Associated Disease (PCVAD) Segment held the largest Porcine Vaccine market share in 2021. This growth is owing to the increasing predominance of Porcine Circovirus Associated Disease (PCVAD) among pigs worldwide. PCVAD are multifactorial ailments, brought about by stress conditions like great pig density, poor ventilation, weaning stress and co-infections with additional pathogens. Porcine Circovirus Type 2 (PCV2) duplicates in lymphocytes and is spread around the body by way of macrophages. The surging count of commercially accessible PCVAD vaccines is further propelling the growth of the Porcine Circovirus Associated Disease (PCVAD) segment.
Furthermore, the Diarrhoea segment is estimated to grow with the fastest CAGR of 8.4% during the forecast period 2022-2027 owing to the proliferating breeding of pigs in farms for meat and gelatin and the overfeeding of protein diet .
Porcine Vaccine Market Segment Analysis - By Technology
The Porcine Vaccine Market based on technology can be further segmented into Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines and Others. The Inactivated Vaccines Segment held the largest Porcine Vaccine market share in 2021. This growth is owing to the effortless accessibility and the reduced hazard of revert reaction of destroyed viruses amidst swine. Information on different virus inactivation strategies, adjuvants, nanoparticle-based vaccine delivery systems, DNA vaccines and recombinant subunit vaccines generated utilizing baculovirus, plant and replication-deficient viruses as vector vaccines has been furnished. The reduced cost and novel innovations by key players are propelling the growth of this segment.
Furthermore, the Live Attenuated Vaccines segment is estimated to grow with the fastest CAGR of 8.2% during the forecast period 2022-2027 owing to the surging investigations conducted for assessing the efficiency of an attenuated live vaccine against highly pathogenic porcine reproductive and respiratory syndrome virus in young pigs and natural recombinant from Fostera PRRSV vaccine and field strain IA76950-WT termed IA70388-R being investigated.
Porcine Vaccine Market Segment Analysis - By Geography
The Porcine Vaccine Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and Rest of the World. North America(Porcine Vaccine Market) held the largest Porcine Vaccine market share with 36% of the overall market in 2021. This growth is owing to the increasing predominance of swine ailments requiring the application of medications like improvac in the North American region. The heightening per capita animal healthcare spending and progress in vaccine development in the U.S are further propelling the growth of the Porcine Vaccine Market in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the existence of countries like China which leads the porcine vaccines market in the Asia-Pacific region. Experimental vaccines involve novel DNA vaccines, vectored vaccines and recombinant vaccines The heightening development of porcine vaccines in countries like Vietnam and Philippines is further fueling the progress of the Porcine Vaccine Industry in the Asia-Pacific region.
Porcine Vaccine Market Drivers
Surging Applications of Improvac and Suvaxyn are Projected to Drive the Growth of Porcine Vaccine Market:
Boar taint is the repulsive smell or taste which may be existing in pork or pork products from non-castrated mature male pigs. Boar taint is brought about by the generation and build-up of the natural compounds androstenone and skatole in the fat of these animals. Improvac is utilized as a substitute to physical castration (elimination of the testes) to decrease the existence of these compounds. Improvac also decreases combative and sexual (mounting) attitude in pigs. Improvac can also be utilized in female pigs from 14 weeks of age engaged for market to temporarily restrain ovarian function (suppression of oestrus) in order to decrease the count of unsought pregnancies in gilts planned for butchery and to decrease the connected sexual behavior (standing oestrus). Improvac includes the active substance gonadotropin releasing factor (GnRF) analogue-protein conjugate. Improvac is provided to male and female pigs as two injections with at least a 4 week interval. Suvaxyn PRRS MLV is a veterinary vaccine utilized to safeguard pigs against porcine respiratory and reproductive syndrome (PRRS). This viral ailment of pigs may lead to reduced farrowing (birth) rates, rise in abortions, stillborn, mummified as well as weak live born piglets and demises. There may also be ailment of the airways which can result in high death rates in suckling and weaned pigs. Suvaxyn PRRS MLV includes an altered strain of live PRRS virus, strain 96V198, that has been weakened so that it does not bring about ailment. Suvaxyn P needs to be aseptically introduced 2 mL (2 cc) intramuscularly per animal as part of its dose. The surging applications of Improvac and Suvaxyn are therefore fueling the growth of the Porcine Vaccine Market during the forecast period 2022-2027.
Soaring Applications of Circovac are Expected to Boost the Growth of the Porcine Vaccine Industry:
Circovac is a vaccine utilized to safeguard pigs against porcine circovirus type 2 (PCV2). Circovac is utilized to decrease the alterations in and injury to lymphoid tissues (cells and tissues that constitute the lymphatic system, like lymph nodes) connected with PCV2 infection in piglets and to assist in decreasing the hazard of losing life from this infection. PCV2 infections can generate clinical signs like weight loss or failure to grow, enlarged lymph nodes, difficulty breathing, pale skin and jaundice (yellowing of the skin). Circovac includes an inactivated (killed) porcine circovirus type 2 (PCV2) strain. Circovac is accessible as an emulsion for injection and can only be acquired with a prescription. The vaccine is provided to female pigs prior to and/or at the time of pregnancy. Their piglets then acquire temporary safeguard against PCV2 when they drink the colostrum (first milk) from their vaccinated mothers. This is termed ‘passive immunisation’. In this case, the impact of the vaccine lasts for up to 5 weeks. Circovac can also be provided directly to piglets from three weeks of age (active immunization). In this case, the impact of the vaccine lasts for at least 14 weeks. The soaring applications of Circovac are therefore driving the growth of the Porcine Vaccine Industry thereby contributing to the Porcine Vaccine Industry Outlook during the forecast period 2022-2027.
Porcine Vaccine Market Challenges
Limitations of Vaccine Strategies for Swine Enteric Coronaviruses are Hampering the Growth of the Porcine Vaccine Market:
Circovac® vaccine is indicated for the passive immunization of piglets through the colostrum succeeding vaccination of sows and gilts and as a support in the regulation of Porcine Circovirus Type 2 (PCV2) infection. Efficiency of the vaccine was measured by challenging piglets at up to 5 weeks of age. To improve the level of maternal immunity, the oral route seems to be the most apparent selection for vaccinating the sow. Indeed, nearly all vaccines for enteric coronaviruses are planned to encourage lactogenic immunity by vaccinating the sow, however, most of them are administered through systemic injection. In the absence of efficient vaccines for porcine epidemic diarrhoea virus (PEDV), numerous producers are presently utilizing a lock-down of the barn integrated with feeding back infectious live virus to pregnant sows. However, the duration of immunity frequently does not extend to greater than a few years, relying on the kind of vaccine being utilized with live vaccines usually offering longer lasting immunity. Even subsequent to feed-back, immunity begins to diminish after a relatively brief period of time, frequently even less than a few months. Vaccine type: Inactivated virus (Baek et al., 2016, Frederickson et al., 2014, Berube et al., 2015) has limitations like activating Th2-skewed immune response and requiring adjuvant. Vaccine type: Live-attenuated virus (de Arriba et al., 2002, Sato et al., 2011) has limitations like reversion to virulence and can bring about certain ailment with protection being dose dependent. Vaccine type: Viral vectored (Yuan et al., 2015, Tuboly and Nagy, 2001) has limitations like pre-existing immunity against vector virus. These issues are thus hampering the growth of the Porcine Vaccine Market.
Porcine Vaccine Industry Outlook
Novel product launches, mergers and acquisitions, collaborations, technological advancements, joint ventures, developments and R&D activities are key strategies adopted by players in the Porcine Vaccine Market. The top 10 companies in the Porcine Vaccine market are:
- Zoetis Inc.
- Boehringer Ingelheim
- Ceva Santé Animale
- Merck & Co., Inc.
- Bimeda Animal Health
- Bayer AG
- Bioveta AS
- In May 2021, Zoetis introduced the only vaccine that involves two porcine circovirus type two (PCV2) genotypes (a and b), offering expansive coverage against PCV2 and safeguard against two of the principal pathogens in the global pig industry, PCV2 and Mycoplasma hyopneumoniae. The novel product is planned to inspire both cell-mediated and antibody-based immunity, offering an expansive immune response that imitates a natural infection. CircoMax Myco has displayed strong performance in field conditions, conveying enhancements in average daily gain and close-out weights versus negative controls.
- In April 2021, Zoetis declared the introduction of Librela (bedinvetmab) in the European Union, U.K. and Switzerland. olensia (frunevetmab) will introduce to veterinarians in Europe, U.K. and Switzerland in May. Librela and Solensia efficiently relieve OA pain in dogs and cats for a month with a positive safety profile.
- In March 2021, Zoetis Inc. declared its long-term sustainability goals, which develop on the firm’s aim to care for the world and humankind by progressing care for animals. Under the banner Driven to Care, Zoetis delivers to life its particular dedications to Communities, Animals and the Planet, involving backing of 10 of the 17 United Nations’ Sustainable Development Goals (SDGs). With operations in 45 nations, Zoetis has the worldwide reach and capacities to champion a healthier, more sustainable future for all. This concludes the Porcine Vaccine Industry Outlook.
Report Code: HCR 66727
Report Code: HCR 0226
Report Code: HCR 0397
For more Lifesciences and Healthcare Market reports, please click here